• 海洋塑料污染问题引起了全球范围内的环保行动和政策调整。
  • 随着技术的进步,无人驾驶汽车的测试和部署正在全球范围内展开。
  • 生物技术在医药领域的应用为治疗复杂疾病提供了新的可能性。
  • 全球健康危机凸显了公共卫生体系的重要性和改革的必要性。
  • 智能家居设备的发展正在引领家庭生活向更智能、更环保的方向发展。
  • 社交媒体的算法透明度问题引起了公众的广泛关注。
  • 数字化转型成为企业在疫情后恢复和增长的关键策略。
  • 海洋塑料污染问题引起了全球范围内的广泛关注。
  • 随着人口老龄化,养老服务和健康管理成为社会关注的新焦点。
  • 社交媒体的普及正在重塑政治沟通和公众参与。
  • 云计算的普及正在改变企业的IT基础设施和运营模式。
  • 在线健身和虚拟健身课程在疫情期间迅速流行。
  • 随着人们对健康意识的提高,健康食品和生活方式受到更多关注。
  • 海洋塑料污染问题引发了全球范围内的环保行动。
  • 全球经济不确定性增加,各国政府正积极寻求解决方案。
  • 在线教育平台的兴起为传统教育模式带来了挑战和机遇。
  • 5G技术的普及为物联网和智能设备的发展提供了新动力。
  • 随着人们对健康意识的提高,健康食品和生活方式受到更多关注。
  • 随着环保意识的提高,可持续消费成为新的消费趋势。
  • 电子商务的快速发展对传统零售业造成了巨大冲击。
  • 电动汽车的普及推动了能源行业的绿色转型。
  • 随着全球经济不确定性增加,跨国公司的社会责任和环境影响受到更多审视。
  • 网络安全成为数字化时代的关键挑战。
  • 5G技术的普及为物联网和智能设备的发展提供了新动力。
  • 在线教育平台的兴起改变了传统教育模式。
  • Safety and efficacy of the Novavax vaccine—a narrative review | Choo | Aging Pathobiology and Therapeutics

    Safety and efficacy of the Novavax vaccine—a narrative review

    Sanny Zi Lung Choo, Shyh Poh Teo

    Abstract


    Mass vaccination programs are a public health priority for managing the global coronavirus disease (COVID-19) pandemic. The NVX-CoV2373 vaccine is being developed by Novavax. It consists of a SARS-CoV-2 spike glycoprotein subunit (NVX-CoV2373), which has been shown to have structural stability with pH and temperature perturbations, and the saponin-based Matrix-M adjuvant, which is added to enhance the B- and T-cell-mediated immune response. Animal studies in mice, olive baboons, and cynomolgus macaques demonstrated the potential of this vaccine in protecting the respiratory tract against COVID-19. Subsequent phase 1 and 2 trials then confirmed its safety and the dose-sparing potential of Matrix-M. The results led to the use of a low dose (5 μg) of NVX-CoV2373 in phase 3 trials. In a phase 3 trial involving 14,039 participants, the vaccine efficacy rate was 89.7% (prevention of symptomatic infection). Local and systemic adverse events were mild and self-limiting; commonly reported symptoms included injection-site pain and tenderness, headache, myalgia, and fatigue. A subgroup study confirmed the safety and efficacy of co-administering the NVX-CoV2373 vaccine and the seasonal influenza vaccine. Overall, the vaccine has been found to be safe and effective, meeting the minimum vaccine efficacy rate of 50% to be considered for COVID-19 vaccine emergency use listing approval.

    Keywords: Clinical trials, COVID-19, COVID-19 vaccine, immunology




    Subscribe to receive issue release notifications
    and newsletters from journals